NovoCure Limited

NasdaqGS:NVCR Voorraadrapport

Marktkapitalisatie: US$1.6b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NovoCure Beheer

Beheer criteriumcontroles 4/4

De CEO NovoCure's is Asaf Danziger, benoemd in Jan2002, heeft een ambtstermijn van 22.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.52M, bestaande uit 49.7% salaris en 50.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde $ 237.99K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 6.9 jaar.

Belangrijke informatie

Asaf Danziger

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris49.7%
Dienstverband CEO22.8yrs
Eigendom CEO0.01%
Management gemiddelde ambtstermijn2.5yrs
Gemiddelde ambtstermijn bestuur6.9yrs

Recente managementupdates

Recent updates

Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects

Sep 12
Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects

NovoCure Limited: A Post Q2 Analysis

Jul 26

NovoCure Limited Q1 Earnings: Core Business Accelerating

May 03

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

Apr 08
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure: Sell The METIS-Inspired Rally

Mar 28

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03
Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13
Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15
Is NovoCure (NASDAQ:NVCR) A Risky Investment?

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24
A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10
Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: See Past Market Myopia And Buy The Dip

Sep 27

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

Analyse CEO-vergoeding

Hoe is Asaf Danziger's beloning veranderd ten opzichte van NovoCure's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$169m

Mar 31 2024n/an/a

-US$193m

Dec 31 2023US$2mUS$756k

-US$207m

Sep 30 2023n/an/a

-US$197m

Jun 30 2023n/an/a

-US$174m

Mar 31 2023n/an/a

-US$141m

Dec 31 2022US$2mUS$831k

-US$93m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$68m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$1mUS$876k

-US$58m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

US$12m

Dec 31 2020US$9mUS$782k

US$20m

Sep 30 2020n/an/a

US$19m

Jun 30 2020n/an/a

US$12m

Mar 31 2020n/an/a

US$9m

Dec 31 2019US$7mUS$702k

-US$7m

Sep 30 2019n/an/a

-US$27m

Jun 30 2019n/an/a

-US$41m

Mar 31 2019n/an/a

-US$55m

Dec 31 2018US$5mUS$693k

-US$64m

Sep 30 2018n/an/a

-US$59m

Jun 30 2018n/an/a

-US$59m

Mar 31 2018n/an/a

-US$64m

Dec 31 2017US$4mUS$698k

-US$62m

Compensatie versus markt: De totale vergoeding ($USD 1.52M ) Asaf } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Asaf is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Asaf Danziger (58 yo)

22.8yrs

Tenure

US$1,521,026

Compensatie

Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
William Doyle
Executive Chairman20.8yrsUS$1.43m0.51%
$ 8.1m
Asaf Danziger
CEO & Director22.8yrsUS$1.52m0.014%
$ 224.1k
Ashley Cordova
Chief Financial Officer4.1yrsUS$6.32m0.085%
$ 1.3m
Barak Arye
General Counsel2.5yrsUS$4.86m0.019%
$ 310.0k
Frank Leonard
Executive VP & President of Novocure Oncology4.1yrsUS$5.04m0.053%
$ 843.5k
Yoram Palti
Founder & CTO24.8yrsUS$282.51kgeen gegevens
Mukund Paravasthu
Chief Operating Officerno datageen gegevensgeen gegevens
Moshe Giladi
Chief Science Officer1.8yrsgeen gegevens0.0065%
$ 103.2k
Ingrid Goldberg
VP of Investor Relationsno datageen gegevensgeen gegevens
Michael Puri
Chief Human Resources Officer1.1yrsgeen gegevens0.0016%
$ 25.5k
Uri Weinberg
Chief Innovation Officer1.8yrsgeen gegevens0.057%
$ 910.7k
Piet Hinoul
Senior VPno datageen gegevensgeen gegevens

2.5yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NVCR wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
William Doyle
Executive Chairman20.8yrsUS$1.43m0.51%
$ 8.1m
Asaf Danziger
CEO & Director12.8yrsUS$1.52m0.014%
$ 224.1k
Jeryl Hilleman
Independent Director6.3yrsUS$446.09k0.0023%
$ 37.3k
David Hung
Independent Director6.4yrsUS$426.09k0.0084%
$ 134.6k
Timothy Scannell
Independent Director3.7yrsUS$448.53k0.0036%
$ 57.8k
Kinyip Leung
Independent Director13yrsUS$435.53k0.073%
$ 1.2m
William Vernon
Lead Independent Director18.8yrsUS$475.53k0.15%
$ 2.4m
Martin Madden
Independent Director7.4yrsUS$446.09k0.014%
$ 229.9k
Kristin Stafford
Independent Director1.6yrsUS$696.94k0%
$ 0
Allyson Ocean
Independent Director1.7yrsUS$697.26k0%
$ 0

6.9yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NVCR wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.9 jaar).